Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion

Am J Obstet Gynecol. 2008 Oct;199(4):e5-6. doi: 10.1016/j.ajog.2008.06.051.

Abstract

Peripartum cardiomyopathy (PPCM) is a rare disease of unclear etiology with a frequent poor outcome, despite optimal medical therapy. Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bromocriptine / pharmacology
  • Bromocriptine / therapeutic use*
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / metabolism
  • Cathepsin D / metabolism
  • Female
  • HELLP Syndrome*
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism
  • Hormone Antagonists / pharmacology
  • Hormone Antagonists / therapeutic use*
  • Humans
  • Myocardium / metabolism
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Complications, Cardiovascular / metabolism
  • Prolactin / antagonists & inhibitors

Substances

  • Hormone Antagonists
  • Bromocriptine
  • Prolactin
  • Cathepsin D